Episode Details
Back to Episodes
PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape
Description
In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:
- Importance of germline and somatic testing
- Adverse events associated with PARP inhibitors
- Maintenance therapy in pancreatic cancer
Presenters:
Philip Agop Philip, MD, PhD, FRCP
Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan
Elena Gabriela Chiorean, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
University of Washington
Member
Fred Hutchinson Cancer Research
Seattle, Washington
Content based on an online CME program supported by an educational grant from AstraZeneca.
Link to full program:
https://bit.ly/3jEehCc
Link to associated downloadable PDF:
https://bit.ly/3nSfTcR
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.